Home › Premarket Biotech Digest: Gilead Gets A Boost, Zafgen's Beloranib Program, Relypsa Gets FDA Nod
 

Keywords :   


Premarket Biotech Digest: Gilead Gets A Boost, Zafgen's Beloranib Program, Relypsa Gets FDA Nod

2015-10-24 12:08:16| Biotech - Topix.net

Parkinson's is very difficult to diagnose- in fact, there's no real diagnostic test for PD. A doctor usually looks at your medical history, maybe some changes in behavior, and may conduct blood tests and scans to eliminate other diseases.

Tags: program boost digest biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05WCC Re-elects Tom Bowtell for Second Term as President, Recognizes Contributions of Andy Doyle
20.05DKSH Extends Distribution Agreement with KRONOS in Asia Pacific
20.05NABC hosts foreign animal disease tabletop exercise
20.05Printed Easy increases capacity by 300% with Durst
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05IMDA launches annual IMDA Awards Competition
20.05Registration opens for FTAs Fall Technical Conference 2024
More »